These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
529 related articles for article (PubMed ID: 17145880)
1. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Kahl P; Gullotti L; Heukamp LC; Wolf S; Friedrichs N; Vorreuther R; Solleder G; Bastian PJ; Ellinger J; Metzger E; Schüle R; Buettner R Cancer Res; 2006 Dec; 66(23):11341-7. PubMed ID: 17145880 [TBL] [Abstract][Full Text] [Related]
2. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer. Heemers HV; Regan KM; Dehm SM; Tindall DJ Cancer Res; 2007 Nov; 67(21):10592-9. PubMed ID: 17975004 [TBL] [Abstract][Full Text] [Related]
4. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate. Kinoshita M; Nakagawa T; Shimizu A; Katsuoka Y Int J Urol; 2005 Apr; 12(4):390-7. PubMed ID: 15948728 [TBL] [Abstract][Full Text] [Related]
5. Expression of the transcriptional coregulator FHL2 in human breast cancer: a clinicopathologic study. Gabriel B; Fischer DC; Orlowska-Volk M; zur Hausen A; Schüle R; Müller JM; Hasenburg A J Soc Gynecol Investig; 2006 Jan; 13(1):69-75. PubMed ID: 16378916 [TBL] [Abstract][Full Text] [Related]
6. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy. Giesing M; Suchy B; Driesel G; Molitor D BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074 [TBL] [Abstract][Full Text] [Related]
8. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer. McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747 [TBL] [Abstract][Full Text] [Related]
9. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes. Axlund SD; Lambert JR; Nordeen SK Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772 [TBL] [Abstract][Full Text] [Related]
10. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells. Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer. Mori R; Wang Q; Quek ML; Tarabolous C; Cheung E; Ye W; Groshen S; Hawes D; Togo S; Shimada H; Danenberg KD; Danenberg PV; Pinski JK Anticancer Res; 2008; 28(1B):425-30. PubMed ID: 18383880 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127 [TBL] [Abstract][Full Text] [Related]
13. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. Björkman M; Östling P; Härmä V; Virtanen J; Mpindi JP; Rantala J; Mirtti T; Vesterinen T; Lundin M; Sankila A; Rannikko A; Kaivanto E; Kohonen P; Kallioniemi O; Nees M Oncogene; 2012 Jul; 31(29):3444-56. PubMed ID: 22120715 [TBL] [Abstract][Full Text] [Related]
14. Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. Shin S; Janknecht R Biochem Biophys Res Commun; 2007 Aug; 359(3):742-6. PubMed ID: 17555712 [TBL] [Abstract][Full Text] [Related]
15. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis. Diallo JS; Aldejmah A; Mouhim AF; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F BJU Int; 2008 May; 101(10):1302-9. PubMed ID: 18294307 [TBL] [Abstract][Full Text] [Related]
16. Modulation of aryl hydrocarbon receptor activity by four and a half LIM domain 2. Kollara A; Brown TJ Int J Biochem Cell Biol; 2009 May; 41(5):1182-8. PubMed ID: 19015043 [TBL] [Abstract][Full Text] [Related]
17. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms. Brys M; Stawinska M; Foksinski M; Barecki A; Zydek C; Miekos E; Krajewska WM Oncol Rep; 2004 Jan; 11(1):219-24. PubMed ID: 14654929 [TBL] [Abstract][Full Text] [Related]
18. Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2. Nair SS; Guo Z; Mueller JM; Koochekpour S; Qiu Y; Tekmal RR; Schüle R; Kung HJ; Kumar R; Vadlamudi RK Mol Endocrinol; 2007 Mar; 21(3):613-24. PubMed ID: 17192406 [TBL] [Abstract][Full Text] [Related]
19. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Rosner IL; Ravindranath L; Furusato B; Chen Y; Gao C; Cullen J; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G Urology; 2007 Dec; 70(6):1225-9. PubMed ID: 18158066 [TBL] [Abstract][Full Text] [Related]